Free Trial

Fate Therapeutics (FATE) News Today

Fate Therapeutics logo
$1.35 +0.02 (+1.50%)
As of 04:00 PM Eastern
Fate Therapeutics, Inc. stock logo
249,800 Shares in Fate Therapeutics, Inc. (NASDAQ:FATE) Acquired by XTX Topco Ltd
XTX Topco Ltd bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 249,800 shares of the biopharmaceutical company's stock, valued at appr
Fate Therapeutics, Inc. stock logo
Walleye Capital LLC Has $1.79 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)
Walleye Capital LLC grew its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 1,502.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,083,092 shares of the biopharmaceutical company's stock aft
Fate Therapeutics, Inc. stock logo
Cerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)
Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company's stock after purchasing an additional 8
Fate Therapeutics receives RMAT designation from FDA for FT819
Fate Therapeutics, Inc. stock logo
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of "Hold" from Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average rating of "Hold" from the nine ratings firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What Happened
Fate Therapeutics, Inc. stock logo
FY2025 EPS Forecast for Fate Therapeutics Boosted by Analyst
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earni
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to "Sell" at StockNews.com
StockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.
Fate Therapeutics price target lowered to $2.50 from $3 at BofA
Fate Therapeutics, Inc. stock logo
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company wil
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Price Target Lowered to $3.00 at Stifel Nicolaus
Stifel Nicolaus lowered their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a research report on Thursday.
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Given New $4.00 Price Target at Wells Fargo & Company
Wells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday.
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Earns "Neutral" Rating from Wedbush
Wedbush reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday.
Fate Therapeutics, Inc. stock logo
Needham & Company LLC Reiterates "Hold" Rating for Fate Therapeutics (NASDAQ:FATE)
Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.
Wedbush Remains a Hold on Fate Therapeutics (FATE)
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Expectations By $0.13 EPS
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings Results
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.
Fate Therapeutics price target lowered to $3 from $5 at Stifel
Fate Therapeutics reports Q4 EPS (44c), consensus (42c)
Fate Therapeutics, Inc. stock logo
StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold
StockNews.com raised Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (FATE) Projected to Post Earnings on Monday
Fate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.
Fate Therapeutics, Inc. stock logo
Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday
Fate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.
Fate Therapeutics, Inc. stock logo
FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Leerink Partnrs issued their FY2024 EPS estimates for Fate Therapeutics in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($1.62
Fate Therapeutics, Inc. stock logo
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average recommendation of "Hold" from the ten research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the
Fate Therapeutics, Inc. stock logo
Research Analysts Offer Predictions for FATE Q1 Earnings
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Fate Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical co
Springworks Therapeutics (SWTX) Gets a Buy from Barclays
Mersana Therapeutics (MRSN) Receives a Buy from TD Cowen
Protagonist Therapeutics (PTGX) Gets a Buy from TD Cowen
Fate Therapeutics, Inc. stock logo
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. cut its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 372,507 shares of the biopharmaceut
Fate Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for FATE FY2025 Earnings
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Fate Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post
Fate Therapeutics, Inc. stock logo
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has received an average recommendation of "Hold" from the ten ratings firms that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating
Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

FATE Media Mentions By Week

FATE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FATE
News Sentiment

1.38

0.72

Average
Medical
News Sentiment

FATE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FATE Articles
This Week

3

3

FATE Articles
Average Week

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FATE) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners